Vanderbilt University Medical Center | Strategic Alliance Partners

“We are truly embarking at this moment on the next frontier in urology with these types of cellular therapies,” says Melissa R. Kaufman, MD, PhD.

In this interview, Nicole L. Miller, MD, discusses her institution’s enhanced recovery after surgery protocol for ureteroscopy, which eliminates the use of opioids in patients undergoing this common procedure.

Advances allow for more accurate detection of metastatic disease.

The final KEYNOTE-426 analysis represents the longest follow-up of a checkpoint inhibitor plus a VEGF/VEGFR inhibitor in frontline clear cell RCC, according to the investigators.

The Uro-G single-use device arrives at a time when the FDA is actively investigating reports of infections associated with reusable cystoscopes.

“As we suspected, the more work interfered with their freedom to use the restroom, the fewer times they urinated during the work day,” says W. Stuart Reynolds, MD, MPH, FACS.

The FDA has approved tivozanib for kidney cancer.

Investigators conducted a systematic literature review and meta-analysis assessing the impact of 3 months or longer anticholinergic use on the risk of multiple subtypes of incident dementia

The paper is meant to serve as a single source of information for helping patients with bladder cancer.

The OASIS study is examining the RENOVA iStim implantable tibial neuromodulation system for the treatment of women with overactive bladder.

A multidisciplinary panel outlines criteria for stratifying risk for genitourinary malignancy in patients with microhematuria.

Treatment with litoxetine, an investigational oral selective serotonin reuptake inhibitor, led to nearly 22% of patients becoming continent.

Outpatient artificial urinary sphincter insertion is likely a viable option based on an analysis of immediate postoperative complications and pain control.

A significant trend is occurring in the management of urethral stricture, with increased utilization of urethroplasty and decreased utilization of repeat endoscopic procedures, researchers at the University of Washington in Seattle report.

Several decades of data show that Black men are less likely to be screened and treated for prostate cancer than their white counterparts. In this interview, Kelvin A. Moses, MD, PhD, of Vanderbilt University Medical Center, Nashville, TN discusses the reasons for these disparities and how practicing urologists can address them.